Physician profile
Ernest Han
NPI 1942357744
$4,765.41
in general payments reported to CMS, 2019-2025
27 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $250 · 2021: $779 · 2022: $842 · 2023: $612 · 2024: $815 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $527.99 | 2019-2025 | Farxiga |
| Vifor Pharma, INC. | $518.44 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $489.78 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $440.09 | 2019-2024 | Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $430.62 | 2021-2025 | |
| Horizon Therapeutics Plc | $407.49 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $298.81 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $254.74 | 2020-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $193.84 | 2020-2025 | |
| Aurinia Pharma U.S., INC. | $168.41 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $158.01 | 2024-2025 | |
| Daiichi Sankyo INC. | $156.60 | 2019-2024 | Injectafer |
| Akebia Therapeutics INC | $120.24 | 2019-2021 | |
| Outset Medical INC | $109.54 | 2022 | |
| Calliditas Therapeutics US INC. | $96.45 | 2023-2025 | Tarpeyo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.97 | 2021-2025 | Ultomiris |
| Lilly USA, LLC | $58.59 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.33 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $40.09 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $38.73 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $24.14 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $23.65 | 2019 | |
| Ardelyx, INC. | $19.14 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2020 | |
| Glaxosmithkline, LLC. | $15.62 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.83 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.